Skip to Main Content

The nonprofit Sabin Vaccine Institute is taking over development of vaccines to protect against two species of Ebola and a related virus, Marburg, acquiring the rights from GSK, the two entities announced Tuesday.

The transfer of the rights for the vaccines will put back into development a vaccine that GSK had shelved after the West African Ebola outbreak of 2014-2016. No money is changing hands; GSK is giving the rights to the institute.


The institute will develop the vaccines in collaboration with the National Institute of Health’s Vaccine Research Center. Scientists from the VRC originally designed the vaccines, which all use the same approach to inducing immunity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!